Marker Therapeutics, Inc. (MRKR) stock
MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.83−0.04 (-4.76%)
Close on Nov 16, 2026Market cap $13.82MP/E –Yield –
Earnings
Marker Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2025
$1.23M
-36.0% on a year earlier
EPS, Q3 FY2025
-$0.12
-$0.26 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Marker Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 19, 2026during market hours | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025before the open | $1.23M | -36.0% | -$0.12 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024during market hours | $1.93M | +647.7% | -$0.26 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024during market hours | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024during market hours | $1.24M | – | -$0.27 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | $257.61K | -93.5% | -$0.34 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023during market hours | $762.66K | -3.5% | $0.29 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022during market hours | $3.95M | – | -$0.08 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022during market hours | $790.51K | – | -$0.11 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 13, 2022before the open | $964.32K | – | -$0.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 18, 2022during market hours | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | – | – | -$0.15 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020during market hours | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020during market hours | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 12, 2019during market hours | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 9, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 9, 2019during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Marker Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Marker Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Marker Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- News
- News
- Update
- Update
- Update
- News
- News
- Results
- News
- News
- News
- Results
See a number that looks wrong?